Molbio Diagnostics IPO Review: Can Its Recurring Revenue Model Support the Valuation?

Healthcare diagnostics is gradually moving away from large laboratories toward faster testing closer to the patient, and Molbio Diagnostics has built its business around that shift. The company is coming out with a ₹939.7 crore IPO, of which only ₹200 crore is fresh capital, while the remaining amount is an Offer for Sale by existing shareholders. At the upper price band of ₹807, the company is seeking a valuation of around ₹9,300 crore.

What makes Molbio Diagnostics IPO interesting is not just its financial growth, but its unique business model that generates recurring revenue long after a diagnostic machine is sold. The bigger question is whether this technology-led business, despite its dependence on government TB programs, deserves the valuation it is asking for.

In this review, we'll break down Molbio's business, growth opportunity, strengths, risks, valuation, and what retail investors should really focus on.

Molbio Diagnostics IPO Snapshot

Molbio Diagnostics IPO GMP

The Grey Market Premium (GMP) is an unofficial indicator based on market demand and can change rapidly. It does not guarantee listing gains or reflect the intrinsic value of an IPO. Investment decisions should be based on the company's fundamentals, valuation, financial performance, and risks rather than GMP alone. Read our detailed guide on IPO GMP to understand how it works and its limitations.

What Powers Molbio Diagnostics' Growth?

Imagine needing a blood test in a remote village. Normally, the sample would travel to a city laboratory, and the result could take a day or even longer. Molbio is trying to eliminate that wait.

The company has developed Truenat, a portable, battery-powered molecular testing device that works like a mini laboratory. It performs highly accurate PCR (DNA-based) tests for around 30 diseases, including Tuberculosis (TB) and COVID, in roughly an hour without requiring a large laboratory.

Its business model is similar to buying a coffee machine. The machine is purchased once, but customers keep buying coffee capsules. Molbio follows the same approach. It first sells the Truenat device and then earns recurring income by selling disposable test kits, cartridges, chips, and reagents needed for every test.

This recurring revenue is already the backbone of the business. In FY26, test kits contributed nearly 74% of operating revenue, while device sales accounted for about 15%. That means every new machine installed today has the potential to generate revenue for many years through repeat purchases.

The company's biggest customers are government healthcare agencies and international health organisations running public health programmes. It also serves private hospitals and laboratories and has exported more than 12,500 Truenat devices to over 90 countries. Manufacturing is spread across six facilities in India, and the company is further strengthening its innovation capabilities by building a new R&D centre in Bengaluru.

Can Molbio Benefit from Industry Growth?

The opportunity for molecular point-of-care testing is growing rapidly. This market, where diagnostic tests are performed near the patient instead of in a central laboratory, is expected to grow from ₹6,160 crore in FY26 to ₹15,210 crore by FY31, implying a healthy 19.8% CAGR.

Several long-term trends support this growth. Healthcare systems increasingly want faster diagnosis, governments are investing in rural healthcare infrastructure, and hospitals are shifting toward decentralized testing that reduces waiting time and improves patient care.

Molbio is well positioned within this niche. Its Truenat platform is one of only two rapid molecular tests globally approved by the WHO for the initial diagnosis of Tuberculosis, and since 2019 it has accounted for 92% of new TB diagnostic installations under India's National Tuberculosis Elimination Programme. This gives the company a meaningful competitive advantage in one of its largest markets.

However, a growing industry does not automatically guarantee that every company will grow at the same pace. Molbio still earns about 70% of its finished goods revenue from TB diagnostics, while the broader molecular diagnostics industry is expanding into areas such as cancer, genetic testing, and hormone disorders. In addition, government agencies account for the majority of its sales, making growth dependent on public healthcare spending and procurement cycles.

The biggest long-term opportunity therefore lies not just in the industry's expansion but in Molbio's ability to diversify beyond TB and increase its presence in private healthcare. If it succeeds, it could capture a much larger share of this fast-growing market.

What Makes Molbio Diagnostics Strong?

One of Molbio's biggest strengths is its razor-and-blade business model. Selling a Truenat device is only the beginning of the customer relationship because every diagnostic test requires the company's proprietary consumables. This creates recurring revenue that is generally more predictable than relying only on one-time equipment sales. It also makes it harder for customers to switch, since changing platforms would require replacing both machines and testing workflows.

Another strength is the company's technology leadership. Developing Truenat took 13 years of research, and it remains the only Indian-made rapid molecular test approved by the WHO for initial TB diagnosis. Such products are difficult to replicate because they require years of scientific research, regulatory approvals, and clinical validation. The company's continued investment in research, supported by a team of over 130 scientists, also increases the chances of expanding into new disease segments over time.

Financially, Molbio has demonstrated strong execution alongside business expansion. Revenue and profit have grown rapidly over the past three years while the company has maintained healthy returns on capital. This suggests that management has not only built an innovative product but has also scaled it into a commercially successful business without sacrificing overall capital efficiency.

What Could Go Wrong?

The biggest concern is customer concentration. More than 84% of finished goods sales come from government bodies and international healthcare agencies, while the single largest customer contributes more than half of total sales. This means delays in government procurement, policy changes, or the loss of a major contract could have a meaningful impact on revenue.

The company also remains heavily dependent on one disease area. Around 70% of finished goods revenue comes from TB testing. While TB programmes continue to receive strong support today, any reduction in funding or a shift in healthcare priorities could slow the company's growth unless it successfully expands into other diagnostic categories.

Cash flow is another area investors should monitor. Government customers usually take longer to make payments, resulting in 166 working capital days and receivables exceeding ₹400 crore. At the same time, borrowings have increased sharply following acquisitions, while over 40% of raw materials are imported, exposing the company to currency fluctuations. Together, these factors can put pressure on cash generation even if reported profits continue to grow.

IPO Valuation: Expensive or Reasonable?

At the upper price band, Molbio is valued at a P/E ratio of 56.66x and a market capitalisation of around ₹9,300 crore. At first glance, this may appear expensive. However, it is actually valued below several listed diagnostic companies such as Dr. Lal PathLabs (62.20x), Metropolis Healthcare (63.72x), and Vijaya Diagnostics (81.02x).

The challenge with using only the P/E ratio is that Molbio is not a traditional pathology chain. Unlike service-based diagnostic companies, it develops its own technology and spends heavily on research. In FY26, the company invested ₹87.46 crore, or 6.05% of revenue, in R&D. Since accounting rules treat this entire amount as an expense rather than a long-term investment, reported profits look lower and the P/E ratio appears higher.

Looking at EV/EBITDA before R&D provides a more meaningful perspective. After adding back R&D expenses, the company's valuation works out to around 22.57x EBITDA, giving a clearer picture of the earnings power of the underlying business.

Compared with peers, Molbio also stands out because of its recurring consumables business, manufacturing capabilities, and technology ownership. Its return on net worth is higher than Poly Medicure's and slightly better than Metropolis Healthcare's despite operating at a similar revenue scale. On the other hand, companies like Dr. Lal PathLabs still generate much higher returns because their asset-light business requires significantly lower capital investment.

Overall, the valuation does not appear cheap, but neither does it look unreasonable considering the company's technology platform, recurring revenue model, and long-term investment in innovation.

Author's Take: Should You Apply for the Molbio Diagnostics IPO?

Molbio Diagnostics is not a conventional diagnostics company. It combines proprietary technology, manufacturing, and recurring consumable sales into a business model that has delivered strong revenue growth and healthy profitability over the past few years. Its leadership in rapid molecular TB testing and continued investment in R&D provide a solid foundation for future expansion.

At the same time, investors should not ignore the risks. The business remains heavily dependent on government healthcare programmes and TB diagnostics, while long working capital cycles and higher debt could weigh on cash flows if growth slows.

From a valuation perspective, the IPO appears broadly reasonable when compared with listed peers, especially after considering the impact of R&D spending on reported earnings.

Overall, this looks like a cautiously positive IPO. The business quality and long-term industry opportunity are attractive, but future returns will depend on how successfully Molbio diversifies beyond TB, expands its private healthcare presence, and converts its technological leadership into broader commercial growth.

Read the RA disclaimer here.